1. i've read the Nature article and I don't see that anywhere. Can you please point out where it says that (in the article, I don't want a reference to what you or any other poster made up and may have posted on here previously). Somehow I don't think you'll be able to. 2. manufacturing is outsourced. Fuji recently announced an additional $2bn cell manufacturing plant to add to their existing plants, somehow I don't think it's to produce 1,200 doses.
Already know you don't have a factual answer so back on ignore.
Sigmadelta, good question, i'd also like to know but I don't think anyone knows the answer until phase 3 trials are complete and regulatory approvals and large manufacturing quantities need to be negotiated. Clearly the cells for the OA trial didn't make a huge dent in cash flow but this was only 100s of recipients. We also don't know what our product would sell for which I expect will be influenced by manufacturing costs. One benchmark we have is MSB is selling GvHD for I believe $250k per patient but I expect this fee will come down enormously over time, particularly as manufacturing efficiencies increase.
CYP Price at posting:
69.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)